President of the Board at Council of European BioRegions - CEBR
Dechamps is a biologist with extensive experience of more than 30 years in the Pharmaceutical industry, with expertise in market development for new products including infectious diseases, immunological disorders, cancer, CNS diseases and vaccines at corporate pharma companies including Glaxo, Glaxo Wellcome and GSK. In 2009 he became Head of the European Mid-Size Countries Region at ViiV Healthcare, a spin out company created by GSK and Pfizer where he created and managed 4 ViiVHC Companies and built a European Commercial – Market Access Operations team dedicated to the launch of the new assets of ViiVHC. Since 2016 Marc has supported biotechnological start-up companies in the field of gene and cell therapies with strategic advising and management leadership. Before joining BioWin Marc served as interim CEO of eTheRNA, Immunotherapies a Belgian clinical stage biotech company, involved in Immuno-oncology.
Parallel Session: Hands-on acceleration and sustainability of healthcare innovation in COVID-19 times
- 8 November, 2021
- 10:00 - 11:30